Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/142522
Full metadata record
DC FieldValueLanguage
dc.creatorPereira-Silva, R
dc.creatorCosta-Pereira, JT
dc.creatorAlonso, R
dc.creatorSerrão, P
dc.creatorMartins, I
dc.creatorNeto, FL
dc.date.accessioned2022-08-01T11:22:20Z-
dc.date.available2022-08-01T11:22:20Z-
dc.date.issued2020
dc.identifier.issn1661-6596
dc.identifier.urihttps://hdl.handle.net/10216/142522-
dc.description.abstractThe noradrenergic system is paramount for controlling pain and emotions. We aimed at understanding the descending noradrenergic modulatory mechanisms in joint inflammatory pain and its correlation with the diffuse noxious inhibitory controls (DNICs) and with the onset of anxiodepressive behaviours. In the complete Freund’s adjuvant rat model of Monoarthritis, nociceptive behaviors, DNICs, and anxiodepressive-like behaviors were evaluated. Spinal alpha2-adrenergic receptors (a2-AR), dopamine beta-hydroxylase (DBH), and noradrenaline were quantified concomitantly with a2-AR pharmacologic studies. The phosphorylated extracellular signal–regulated kinases 1 and 2 (pERK1/2) were quantified in the Locus coeruleus (LC), amygdala, and anterior cingulate cortex (ACC). DNIC was attenuated at 42 days of monoarthritis while present on days 7 and 28. On day 42, in contrast to day 28, noradrenaline was reduced and DBH labelling was increased. Moreover, spinal a2-AR were potentiated and no changes in a2-AR levels were observed. Additionally, at 42 days, the activation of ERKs1/2 was increased in the LC, ACC, and basolateral amygdala. This was accompanied by anxiety-and depressive-like behaviors, while at 28 days, only anxiety-like behaviors were observed. The data suggest DNIC is attenuated in prolonged chronic joint inflammatory pain, and this is accompanied by impairment of the descending noradrenergic modulation and anxiodepressive-like behaviors.
dc.description.sponsorshipThis study was funded by Project NORTE-01-0145-FEDER-000008 supported by the North Portugal Regional Operational Programme (Norte 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (ERDF).
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofInternational Journal of Molecular Sciences, vol.21(8):2973
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.meshAnimals
dc.subject.meshArthritis / complications
dc.subject.meshArthritis / metabolism
dc.subject.meshChronic Pain / etiology
dc.subject.meshChronic Pain / therapy
dc.subject.meshDiffuse Noxious Inhibitory Control
dc.subject.meshDisease Models, Animal
dc.subject.meshDisease Susceptibility
dc.subject.meshMitogen-Activated Protein Kinase 1 / metabolism
dc.subject.meshMitogen-Activated Protein Kinase 3 / metabolism
dc.subject.meshNorepinephrine
dc.subject.meshRats
dc.subject.meshSpinal Cord / metabolism
dc.titleAttenuation of the diffuse noxious inhibitory controls in chronic joint inflammatory pain is accompanied by anxiodepressive-like behaviors and impairment of the descending noradrenergic modulation
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.3390/ijms21082973
dc.relation.publisherversionhttps://www.mdpi.com/1422-0067/21/8/2973
Appears in Collections:ICBAS - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.3390-ijms21082973.pdf3.24 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons